Europe Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)
Market Introduction
The Europe gastroparesis market includes the consolidated markets for Germany, France, United Kingdom, Italy, Spain, and Rest of Europe. Europe occupies a significant position in the global gastroparesis market and is expected to register robust growth rate over the forecast period. Increasing incidences of gastroparesis coupled with growing research and developments for gastrointestinal conditions are likely to be the major factors driving the growth of the market in the European region. The Rest of Europe in gastroparesis comprises Switzerland, Netherlands, Ireland, Belgium, Denmark, and others. The rising incidence of gastroparesis along with increasing research and development activities are likely to support the growth of the market in these countries. Switzerland, Sweden, and Denmark are emerging as countries performing remarkable scientific innovations in terms of development of biological molecules and drugs. This capability of these countries for new drug development offers lucrative opportunity for growth of the rest of Europe gastroparesis market. Furthermore, aging population coupled with growing prevalence of diabetes are also projected to accelerate the market growth by 2027.
Among all European countries, Spain, Italy, Germany, France, and the UK are most affected due to the increasing number of COVID-19 cases and associated deaths. Resulting to these situations, the regional government announced local restrictions in countries and ordered to follow the lockdown protocols. Growing research activities about adverse drug reaction of anti-emetics in combination with COVID 19 anti-viral drugs is offering conclusion about the impact of COVID-19 pandemic on the gastroparesis market. For instance, according to research European Journal of Gastroenterology and a study published in November 2020, prokinetic and antiemetic agent domperidone could lead to dangerous interaction with antiviral drugs darunavir/cobicistat and lopinavir/ritonavir (which is preferably used in treatment of coronavirus disease) and their co-administration is considered contraindication. Moreover, due to ongoing impact of COVID-19 pandemic, certain trials have been re-scheduled or delayed. Thus, the above-mentioned factor is likely to create negative impact on the growth of market in the Europe.
Get more information on this report :
Market Overview and Dynamics
The gastroparesis market in Europe is expected to grow from US$ 1,283.40 million in 2020 to US$ 1,683.42 million by 2027; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027. Advanced computational technologies such as artificial intelligence (AI) and biomedical engineering hold potential to offer promising solutions for the treatment of gastroparesis. The efficacy of gastric electrical stimulation in improving gastric emptying and reducing symptoms severity in patients with diabetes gastroparesis has already been proven. Moreover, several devices have been awarded with the FDA approval for the treatment of this condition. In February 2015, Medtronic received FDA approval for its Enterra gastric neurostimulator device, which is already available in the market for the treatment of gastroparesis. The device won a regulatory approval for its use in the prevention of nausea and vomiting associated with the idiopathic and diabetic gastroparesis. Thus, the growing emphasis on the research pertaining to the gastric electrical stimulation therapy is anticipated to encourage new technology developments in the gastroparesis market, eventually allowing the market players to come up with better alternatives for the existing gastroparesis treatment modalities in the coming years.
Key Market Segments
The Europe gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The Europe gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The Europe gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the Europe gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the Europe gastroparesis market is segmented into France, Germany, Italy, Spain, UK, and rest of Europe. Germany held the largest market share in 2019.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.
Reasons to buy report
- To understand the Europe gastroparesis market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe gastroparesis market.
- Efficiently plan M&A and partnership deals in Europe gastroparesis market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe gastroparesis market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
Europe Gastroparesis Market Segmentation
Europe Gastroparesis Market - By Type
- Idiopathic
- Diabetic
- Post-surgical
- Others
Europe Gastroparesis Market - By Drug Class
- Prokinetic Agents
- Botulinum Toxin Injections
- Antiemetic Agent
Europe Gastroparesis Market – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Europe Gastroparesis Market - By Country
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Europe Gastroparesis Market - Company Profiles
- Allergan Plc
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Gastroparesis Market – By Type
1.3.2 Europe Gastroparesis Market – By Drug Class Type
1.3.3 Europe Gastroparesis Market – By Distribution Channel
1.3.4 Europe Gastroparesis Market – By Country
2. Europe Gastroparesis Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Gastroparesis Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert Opinion
5. Europe Gastroparesis Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Diabetes Mellitus Prevalence on Rise
5.1.2 Geriatric Population Rising
5.2 Market Restraints
5.2.1 Gastroparesis Drugs Having Side Effects
5.3 Market Opportunities
5.3.1 Rising Financial Assistance for Research
5.4 Future Trends
5.4.1.1 Stress on Gastric Electrical Stimulation Therapy Research
5.5 Impact Analysis
6. Gastroparesis Market – Europe Analysis
6.1 Europe Gastroparesis Market Revenue Forecast and Analysis
7. Europe Gastroparesis Market Analysis – By Type
7.1 Overview
7.2 Europe Gastroparesis Market Revenue Share, by Type (2019 and 2027)
7.3 Idiopathic
7.3.1 Overview
7.3.2 Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Diabetic
7.4.1 Overview
7.4.2 Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Post-Surgical
7.5.1 Overview
7.5.2 Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8. Europe Gastroparesis Market Analysis – By Drug Class Type
8.1 Overview
8.2 Europe Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
8.3 Prokinetic Agents
8.3.1 Overview
8.3.2 Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Botulinum Toxin Injection
8.4.1 Overview
8.4.2 Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Antiemetic Agents
8.5.1 Overview
8.5.2 Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9. Europe Gastroparesis Market Analysis – By Distribution Channel
9.1 Overview
9.2 Europe Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
10. Europe Gastroparesis Market – Country Analysis
10.1 Overview
10.1.1 Europe: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.1.2 Germany: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.1 Germany: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.2 Germany Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.3 Germany Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.4 Germany Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.3 UK: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.1 UK: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.2 UK Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.3 UK Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.4 UK Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.4 France: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.1 France: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.2 France Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.3 France Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.4 France Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.5 Spain: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.5.1 Spain: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.5.2 Spain Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.5.3 Spain Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.5.4 Spain Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.6 Italy: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.6.1 Italy: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.6.2 Italy Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.6.3 Italy Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.6.4 Italy Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.7 Rest of Europe: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Rest of Europe: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Rest of Europe Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.7.3 Rest of Europe Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.7.4 Rest of Europe Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Gastroparesis Market
11.1 Europe: Impact Assessment Of COVID-19 Pandemic
12. Gastroparesis Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Gastroparesis Market, 2018-2020
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Allergan Plc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bausch Health Companies Inc. (Salix Pharmaceuticals)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson and Johnson Services, Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Pfizer Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Ipca Laboratories Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 2. Germany Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 3. Germany Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. UK Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 5. UK Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 6. UK Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. France Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 8. France Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 9. France Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Spain Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 11. Spain Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 12. Spain Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 13. Italy Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 14. Italy Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 15. Italy Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 16. Rest of Europe Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 17. Rest of Europe Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 18. Rest of Europe Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 19. Recent Inorganic Growth Strategies in the Gastroparesis market
Table 20. Glossary of Terms, Gastroparesis Market
LIST OF FIGURES
Figure 1. Europe Gastroparesis Market Segmentation
Figure 2. Europe Gastroparesis Market Segmentation, By Country
Figure 3. Europe Gastroparesis Market Overview
Figure 4. Idiopathic Segment Held Largest Share of Europe Gastroparesis Market
Figure 5. Germany to Show Remarkable Growth During Forecast Period
Figure 6. Europe PEST Analysis
Figure 7. Europe Gastroparesis Market Impact Analysis of Drivers and Restraints
Figure 8. Europe Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027
Figure 9. Europe Gastroparesis Market Revenue Share, by Type (2019 and 2027)
Figure 10. Europe Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Europe Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Europe Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. Europe Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Europe Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
Figure 15. Europe Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 16. Europe Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Europe Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. Europe Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 19. Europe Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Europe Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Europe Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Europe: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 23. Europe: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 24. Germany: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 25. UK: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 26. France: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. Spain: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 28. Italy: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 29. Rest of Europe: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Impact of COVID-19 Pandemic in European Country Markets
Figure 31. Growth Strategies in the Gastroparesis Market, 2018-2020
- Allergan Plc
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe gastroparesis market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe gastroparesis market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the gastroparesis market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution